6,215 reports of this reaction
1.5% of all PANTOPRAZOLE SODIUM reports
#15 most reported adverse reaction
RENAL INJURY is the #15 most commonly reported adverse reaction for PANTOPRAZOLE SODIUM, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 6,215 FDA adverse event reports linking PANTOPRAZOLE SODIUM to RENAL INJURY. This represents approximately 1.5% of all 411,823 adverse event reports for this drug.
PANTOPRAZOLE SODIUM has an overall safety score of 85 out of 100. Patients taking PANTOPRAZOLE SODIUM who experience renal injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL INJURY is a less commonly reported adverse event for PANTOPRAZOLE SODIUM, but still significant enough to appear in the safety profile.
In addition to renal injury, the following adverse reactions have been reported for PANTOPRAZOLE SODIUM:
The following drugs have also been linked to renal injury in FDA adverse event reports:
RENAL INJURY has been reported as an adverse event in 6,215 FDA reports for PANTOPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL INJURY accounts for approximately 1.5% of all adverse event reports for PANTOPRAZOLE SODIUM, making it a notable side effect.
If you experience renal injury while taking PANTOPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.